This paper is methodological (statistical theory) one.
The authors are considering the analysis population (or method) for non-inferiority trials with treatment cross-over. The conclusion is that the AT approach has good properties under the small % of treatment swiching. I would like to have comments about the use of the g-estimation, which is more suitable for the analysis of non-inferiority trials with non-compliance. The authors should discuss this point.
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GENERAL COMMENTS
The authors have sought to investigate the impact of early (i.e., before actual treatment) crossover and of different analysis populations on type I error rates of simulated non-inferiority trials. Although I am a clinician with a keen interest in research methodology, the fact that I am not a statistician prevents me from providing a more in-depth critique of the methods used and their robustness to the many assumptions required. Nevertheless, this is an interesting study of an important issue. I believe there two sides to the findings: if, on the one hand, they suggest that one should consider more suitable populations for analysis than the ITT and PP populations, in my mind they are reassuring in the sense that the inflation of type I error rates are not of unacceptable magnitudes. Perhaps one point worthy of further discussion by authors is the following. As appropriate, one-sided alpha of 2.5% was used in simulations. However, this corresponds to results at the two-sided alpha level of 5.0%, a reason why two-sided 95% confidence intervals are used in the interpretation of non-inferiority trials. Authors should discuss whether their simulated type I error rates correspond to one-sided or two-sided rates, something which does not appear to be stated explicitly in the current version of the manuscript.
Minor suggested corrections: Page 8, line 46: please clarify whether 'survival times' refer to 'localrecurrence-free survival times'. Page 9, line 11: please replace 'and' by 'at' in 'if they remained event-free (...)'. Page 11, line 39: please delete ', or' at the end of the sentence.
VERSION 1 -AUTHOR RESPONSE
Reviewer #1
1.This paper is methodological (statistical theory) one. The authors are considering the analysis population (or method) for non-inferiority trials with treatment cross-over. The conclusion is that the AT approach has good properties under the small % of treatment switching. I would like to have comments about the use of the g-estimation, which is more suitable for the analysis of non-inferiority trials with non-compliance. The authors should discuss this point.
The reviewer makes a good point. Randomized-based methods such as the rank preserving structural failure time (RPSFT) models using g-estimation are built on the counterfactual framework have shown to reduce bias in trials with non-compliance under certain scenarios and strict assumptions. However, these models are complex and were not evaluated for this reason. We have added this to the discussion on page 13.
Reviewer #2
1.The authors have sought to investigate the impact of early (i.e., before actual treatment) crossover and of different analysis populations on type I error rates of simulated non-inferiority trials. Although I am a clinician with a keen interest in research methodology, the fact that I am not a statistician prevents me from providing a more in-depth critique of the methods used and their robustness to the many assumptions required. Nevertheless, this is an interesting study of an important issue. I believe there two sides to the findings: if, on the one hand, they suggest that one should consider more suitable populations for analysis than the ITT and PP populations, in my mind they are reassuring in the sense that the inflation of type I error rates are not of unacceptable magnitudes. Perhaps one point worthy of further discussion by authors is the following. As appropriate, one-sided alpha of 2.5% was used in simulations. However, this corresponds to results at the two-sided alpha level of 5.0%, a reason why two-sided 95% confidence intervals are used in the interpretation of non-inferiority trials. Authors should discuss whether their simulated type I error rates correspond to one-sided or twosided rates, something which does not appear to be stated explicitly in the current version of the manuscript.
The design of the simulations used a one-sided alpha of 0.025 and the corresponding empirical type I error rates are also one-sided. This has been added to the manuscript on page 9.
